Stay updated on Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial

Sign up to get notified when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.
    Difference
    0.7%
    Check dated 2025-07-04T02:15:04.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.6%
    Check dated 2025-06-19T19:04:55.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T08:06:23.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.9%
    Check dated 2025-05-29T05:44:06.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-04-30T13:42:46.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new collaborators, a revision number change, and the introduction of a new study identifier for advanced melanoma. Notably, extensive details regarding the study's objectives, inclusion and exclusion criteria, and safety protocols have been removed.
    Difference
    44%
    Check dated 2025-04-16T01:34:15.000Z thumbnail image

Stay in the know with updates to Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Imprime PGG+Pembrolizumab in Melanoma & TNBC Clinical Trial page.